Skip to main content

What Merck's Quarter ended Sep 30, 2026 10-Q says: 4 signals

Merck filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses acquisition completed, automation investment and compliance burden.

Public (MRK)Pharmaceutical Manufacturing10,000+ employeesmerck.comLinkedIn

Get Merck's live signals in Claude or ChatGPT, or by API

AskWhat changed at Merck this week? Use Autobound signals for merck.com.
Filed
Nov 4, 2026
Period
Quarter ended Sep 30, 2026
Filings
3
Signals
15

Source: Autobound Signal API · 95 signals tracked for Merck · updated

10-Q · latest 10

What Merck's 10-Q filings say

  1. 10-Q · Quarter ended Sep 30, 2026

    Filed · 4 signals

    SEC EDGAR
  2. 10-Q · Quarter ended Jun 30, 2026

    Filed · 6 signals

    SEC EDGAR
  3. 10-Q · Quarter ended Mar 31, 2026

    Filed · 5 signals

    SEC EDGAR

Showing 10 of 15 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Merck earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Generic competition and LOEs driving over $2B in headwindsMerck anticipates over $2 billion in revenue headwinds in 2027 stemming from loss of exclusivity (LOE) and generic erosion across mature franchises. This includes generic entrants against BRIDION, Januvia, and Adempas, alongside moderating growth for KEYTRUDA. Sales teams can target units affected by patent expirations as the company seeks operational offsets.
Moderna collaboration advances phase 3 mRNA cancer vaccine trialsMerck presented positive Phase 3 results for entismodigene, an individualized neoantigen mRNA cancer vaccine developed with Moderna, in combination with KEYTRUDA. The companies are currently engaged with the FDA on regulatory submissions and advancing multiple Phase 2 and Phase 3 INTerpath trials across oncology indications.
Dutch court injunction temporarily halts subcutaneous KEYTRUDA rolloutA Dutch court issued an injunction temporarily restricting Merck from supplying subcutaneous pembrolizumab (KEYTRUDA QLEX) in several European markets due to patent litigation surrounding the hyaluronidase component. While the US and core high-adoption markets remain unaffected, commercialization is suspended in Italy, Denmark, Netherlands, France, Belgium, and Ireland pending appeal.
Capital allocation strategy maintains $3B annual share repurchase planMerck reiterated its capital allocation strategy, which includes maintaining a strong investment-grade credit profile, continuing dividend growth, and executing $3 billion in share repurchases for 2026. Management signaled ongoing financial capacity to fund science-driven business development transactions.
Market-wide vaccine hesitancy and utilization declines impact portfolioMerck reported a 13% decline in US CAPVAXIVE sales due to lower adult pneumococcal vaccination rates, which offset market share gains. Management noted that broader market vaccine hesitancy and reduced utilization are key operational headwinds being monitored heading into 2027.
Ongoing multiyear optimization effort partially offsets operating cost increasesMerck cited ongoing multiyear optimization initiatives that helped mitigate operational expense growth in Q3. Operating expenses expanded 12% to $7.4B, with management continuing to focus on structural efficiencies while ramping R&D pipeline and commercial launch spend.

Signal API · MCP

Track Merck with the Signal API

One POST /v1/companies/enrich call with merck.com returns Merck 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"merck.com","signal_types":["sec-10q"],"limit":20}'

Bulk data

Need this signal for 10,000+ companies?

Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.

Talk to sales

Same industry

Questions about Merck 10-Q

When did Merck file its latest 10-Q?
Merck filed its latest 10-Q (Quarter ended Sep 30, 2026) on Nov 4, 2026. The one before it was filed on Aug 7, 2026.
What did Merck disclose in its latest 10-Q?
From the filing dated Nov 4, 2026: Merck closed $647 million acquisition of TARGAN in July 2026
What did Merck say on its recent earnings calls?
Q3 FY2026: Generic competition and LOEs driving over $2B in headwinds (dated Oct 29, 2026).
Where can I read Merck's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/310158/000031015826000248/mrk-20260930.htm. This page summarizes what the filing says and links to it.

Page updated , the date of the newest row on this page.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →